Media about us

2016-04-04 pharmpro.com

The Race to Create a Biosimilar of Rituximab

The race for the global rituximab market is approaching the finishing line. Mabion S.A., a Polish biotechnology company, is among the leaders of the race.

More: [link]

2016-04-01 firstwordpharma.com

Biosimilar rituximab – many have started – only a few will succeed

Experts agree that it is the only facility for large-scale production of biopharmaceuticals, based fully on the disposables technology (eliminating the product’s contact with the production environment and the machinery) in 100% of the manufacturing chain. This is largest facility operating in this technology worldwide.

More: [link]

2016-04-01 thepharmatimes.in

Biosimilar rituximab – many have started – only a few will succeed

Expiry of the rituximab (MabThera®) patent at the end of 2013 paved the way for the introduction of cheaper versions of the drug by biosimilar manufacturers. Several players, including the largest representatives of the pharmaceutical industry in the world, joined the race to get a piece of the pie – which at that time was worth approx. CHF 7 billion annually . Currently, given the decision taken by i.a. Boehringer Ingelheim to suspend its clinical trial, market experts agree that only a few companies will stay in the game, and among them the first and only Polish biopharmaceutical company – Mabion S.A.

More: [link]

2016-04-01 Forbes (page 76)

Manager who treats

Polish pharmacy is strong in the production of simple generic drugs, but Maciej Wieczorek is the first who has chance to start selling more modern and precise biosimilar drugs and earns millions. Work on specific, meaning Mabion coming to an end.

2016-03-25 biznes.interia.pl

MAB: Mabion SA among the leaders in the race for market rituximab

The company regularly consults the progress of research with the European Medicines Agency within he procedure of scientific advice.

More: [link]

2016-03-25 kierunekfarmacja.pl

Mabion SA among the leaders in the race for global market rituximab

Several players, including the largest representatives of the pharmaceutical industry in the world, joined the race to get a piece of the pie – which at that time was worth approx. CHF 7 billion annually[1]. Currently, given the decision taken by i.a. Boehringer Ingelheim to suspend its clinical trial, market experts agree that only a few companies will stay in the game, and among them the first and only Polish biopharmaceutical company – Mabion S.A.

More:[link]

2016-03-24 rynekaptek.pl

Mabion announces the registration of biosimilar rituximab

Expiry of the rituximab (MabThera®) patent at the end of 2013 paved the way for the introduction of cheaper versions of the drug by biosimilar manufacturers. One of them is Mabion.

More:[link]

2016-03-23 parkiet.com

Mabion getting closer to success

Currently, given the decision taken by i.a. Boehringer Ingelheim to suspend its clinical trial, market experts agree that only a few companies will stay in the game, and among them the first and only Polish biopharmaceutical company – Mabion S.A. i MabionEGFR.

More: [link]

2016-03-07 Parkiet (page 6)

Biotechnology with chance to further rises

Mabion is the closest to enter the drug on the market. The company is at the end of third phase of clinical trials, with regard to the treatment of rheumatic arthritis, in which must be screened more than 800 patients, of which 624 must complete the survey. Now, Mabion still needs to turn 80 patients to the study.

2016-02-23 Parkiet (page 4)

Step by competitor

The aim of Mabion is to get the largest share in the global sales of the drug biosimilar to rituximab, which is used for the treatment of blood cancers such as leukemia or lymphoma and rheumatoid arthritis. It is estimated that this market is currently worth about $ 7 billion annually.

2016-02-23 Puls Biznesu (page 7)

Mabion racing with giant

Mabion racing with giant. Mabion, biotechnology company, is in the final straight in the clinical studies of the pharmaceutical MabionCD20, which finds application in the treatment of blood cancer and rheumatoid arthritis (RA).

2016-02-22 finanse.wp.pl (source: ISBNews)

Mabion complete the process of clinical trials for CD20 by the end of this year

We are currently in talks with several partners, which include companies ready to enter into final trade negotiations. In view of our plans to develop other biosimilars, we find it very important to obtain such a partner or partners for MabionCD20, who will allow us to effectively implement milestones and who will ensure the best conditions for the sale of our drug.

More:[link]

2016-02-22 biznes.pap.pl

Clinical study of the drug MabionCD20 should be completed by the end of ’16

Mabion should complete clinical trials on drug MabionCD20 on the end of 2016 – told Maciej Wieczorek, The President of Mabion. Also reported that the contract with distribution partner should be signed in the next few months.

More:[link]

2016-02-22 rynekaptek.pl

Mabion: we are ready to negotiate trade

Currently, we are at the end of clinical trials of the drug CD20 – said the company’s president, Maciej Wieczorek during the press conference. He added that the registration of the drug will last for approx. 210 days, but the “drug will be ready at any time from the date of registration, because we produce it.”

More:[link]

2016-02-22 wyborcza.biz (source: ISBNews)

Mabion complete the process of clinical trials for CD20 by the end of this year

Mabion predicts that clinical trials on drug MabionCD20 used in the treatment of blood cancers and rheumatoid arthritis (RA) will be completed by the end of 2016 year, said the company’s president Maciej Wieczorek.

More: [link]

2016-02-22 money.pl

Cancer drug. Still a year of research on Polish cancer therapy

MabionCD20 is built on monoclonal antibodies used in the treatment of blood cancers, lymphomas and leukemias, as well as in the treatment of rheumatoid arthritis. The medicine successfully passed the development phase of the manufacturing process and in vitro characterization.

More:[link]

2016-02-22 bankier.pl (source: PAP Biznes)

A clinical study of the drug MabionCD20 should be completed by the end of ’16

Mabion should complete clinical trials on drug MabionCD20 on the end of 2016 – told Maciej Wieczorek, The President of Mabion. Also reported that the contract with distribution partner should be signed in the next few months.

More: [link]

[1] source: Roche Finance Report 2015

2015-10-26 Inwestycje.pl/manager

The successful issue of Mabion shares

Mabion issued 360 thousand. shares – 47 zł per share, which means the value of the issue of  PLN 16.92 mln. Apart from the issue of shares of series M, Mabion signed an agreement with the main shareholders of preliminary agreements cover 340 thousand. N-series shares at an issue price 47 zł per share.

More: [link]


2015-10-23 Biotechnologia.pl (autor: Adam Zalewski)

Innovative bio-business without complexes

Among the elite group of experts was, inter alia, Assoc. Tadeusz Pietrucha, founder and CEO of Bio-Tech Consulting Sp. z.o.o. (…) There is a whole bunch of people, especially the young, who wants to live differently and has no complexes that they were born in Poland. There are some fantastic examples, including such companies as Mabion, Selvita, Oncoarendi which operate without complexes. Mabion already at this point is a company with international scope, and others – also soon to join.

More: [link]


Biosimilars Newsletter Volume 8, October 2015

Mabion Begins Pre-Registration Scientific Advice With The EMA

Mabion has taken the first step to the registration of biosimilar drug MabionCD20 with the EMA. Mabion is receiving scientific advice from the EMA regarding the MabionCD20 drug, a biosimilar of MabThera, used in the treatment of blood cancers and rheumatoid arthritis.

More: [link]

2015-10-22 Wyborcza.biz/Gieldy (source: ISBNews)

Mabion acquired PLN 16.92 million from the issue of shares of series M, plans another issue

Mabion issued 360 thousand. shares – 47 zł per share, which means the value of the issue of  PLN 16.92 mln. Apart from the issue of shares of series M, Mabion signed an agreement with the main shareholders of preliminary agreements cover 340 thousand. N-series shares at an issue price 47 zł per share.

More: [link]

2015-10-19 Pap.pl/Biznes (source: PAP)

Boehringer suspends work on biosimilar rituximab, Mabion wanes competitor

The pharmaceutical company Boehringer Ingelheim stopped works on bio-medicine similar to MabThera/Rituxan (rituximab) – Heidrun Thoma from the press office of the company told PAP. (…) The work on biosimilar rituximab (under the name MabionCD20) leads listed on the Warsaw Stock Exchange Mabion. In June Maciej Wieczorek, Mabion’s CEO, predicted that his company will complete clinical trials in August or September 2016, with the assumption that in February-March 2016 last patient will be given medication.

More: [link]

2015-10-13 Yahoo.com/Finance

Global Protein Expression Systems Market Report 2015: Current Landscape and Future Opportunities

Research and Markets has announced the addition of the “Protein Expression Systems Market: Current Landscape and Future Opportunities” report to their offering. Mabion is one of the companies mentioned in this report.

More: [link]

 

2015-10-09   Biotechnologia.pl/Farmacja (author: Sylwia Korczyńska)

Report from the Conference medicine, pharmacy and cosmetics

Speakers who are experts in country and abroad, during their presentations discussed topics related to innovation, new technologies, source of financing in the data fields. Their experience were presented by practitioners who have managed to succeed in the development of companies. (…) Prof. Tadeusz Pietrucha discussed, on the example of companies co-organized by him, how the innovation is created in industries related to health, and what determines the success on the market. As a first he talked about the company Mabion, which was created in order to market the latest generation of biotech drugs based on humanized monoclonal antibodies.

More: [link]

 

2015-09-28 Pb.pl/PulsBiznesu (author: Tomasz Sadzyński)

Location, people, innovation

The Łódź zone is 1,302 hectares in three voivodeships: Łódzkie, Mazovia and Wielkopolska. (…) Such a model example of development is Mabion, a Polish biotechnology company, which began its operations in the zone as a research and development laboratory. Now the company built a factory that will produce newly invented biotech drugs, mainly anti-cancer.

More: [link]

 

2015-09-29 Biospace.com/News

Mabion Files Application To The Main Pharmaceutical Inspectorate

Mabion SA – the Polish biopharmaceutical company that develops and brings to market latest generation biosimilar drugs – submitted an application to the Main Pharmaceutical Inspectorate for authorization to produce investigational medicinal products in the Scientific-Industrial Complex of Medical Biotechnology. Following the completion of building works in Konstantynów Lódzki, the plant was granted permission for use in May 2015. MabionCD20 will be the first medicine produced commercially at the investment. Mabion has started pre-registration scientific advice for the MabionCD20 drug – for use in the treatment of blood cancers and rheumatoid arthritis (RA) – with the European Medicines Agency, this is a preliminary stage prior to the formal application for the registration of the drug.

More: [link]

 

2015-09-21 Wp.pl/finanse

Mabion files application to the Main Pharmaceutical Inspectorate

Mabion SA submitted an application to the Main Pharmaceutical Inspectorate for authorisation to produce investigational medicinal products in the Scientific-Industrial Complex of Medical Biotechnology – informed CEO Maciej Wieczorek. “The permit from the Main Pharmaceutical Inspectorate will allow – following registration on the market – the commencement of the commercial production of the MabionCD20 drug, used in the treatment of blood cancers and rheumatoid arthritis (RA). While awaiting the decision of the Main Pharmaceutical Inspectorate regarding the Complex in Konstantynów Łódzki, we began pre-registration scientific advice with the European Medicines Agency for MabionCD20 – this is a preliminary stage preceding a formal application for the registration of a drug in the European Union” – said Wieczorek.

More: [link]

2015-09-21 Parkiet.com (author: Kamil Majcher)

Mabion with the application in the Main Pharmaceutical Inspectorate

The company is applying for a license to manufacture investigational medicinal products in the complex Industrial Science and Medical Biotechnology. MabionCD20 will be the first medicine produced commercially in the center. The company has also started a scientific consulting Pre-registration with the European Medicines Agency. Regarding drug. This is a preliminary step before a formal application for registration of a pharmaceutical used for the treatment of blood cancers and rheumatoid arthritis.

More: [link]

2015-09-21 Wyborcza.biz/Giełdy

Mabion files application to the Main Pharmaceutical Inspectorate

Mabion SA submitted an application to the Main Pharmaceutical Inspectorate for authorisation to produce investigational medicinal products in the Scientific-Industrial Complex of Medical Biotechnology – informed CEO Maciej Wieczorek. “The permit from the Main Pharmaceutical Inspectorate will allow – following registration on the market – the commencement of the commercial production of the MabionCD20 drug, used in the treatment of blood cancers and rheumatoid arthritis (RA). While awaiting the decision of the Main Pharmaceutical Inspectorate regarding the Complex in Konstantynów Łódzki, we began pre-registration scientific advice with the European Medicines Agency for MabionCD20 – this is a preliminary stage preceding a formal application for the registration of a drug in the European Union” – said Wieczorek.

More: [link]

2015-09-21 Portalemedyczne.pl

Mabion filed an application in GIF

Polish company specialized in biosimilar drugs filed in the Main Pharmaceutical Inspectorate an application for authorization to manufacture investigational medicinal products in the newly built Scientific-Industrial Complex of Medical Biotechnology.

More: [link]

2015-09-18 Rynekzdrowia.pl/Farmacja

Mabion SA requested permission to manufacture biosimilars

Polish biotech company Mabion SA filed in the Main Pharmaceutical Inspectorate an application for authorization to manufacture investigational medicinal products in the Scientific-Industrial Complex Medical Biotechnology in Konstantynów Łódzki. According to the company, the plant in Konstantynów Łódzki was completed in May 2015. Mabion SA obtained permission to use the plant. The first drug produced commercially in this investment will be MabionCD20.

More: [link]l

2015-09-10 Businesswire.com/news

Research and Markets Non-Small Cell Lung Cancer – Pipeline Review, H1 2015

Research and Markets has announced the addition of the “Non-Small Cell Lung Cancer – Pipeline Review, H1 2015” report to their offering. Mabion is one of the companies mentioned in this report.

More: [link]

2015-09-10 Pharmacychoice.com/news

Metastatic Colorectal Cancer – Pipeline Review, H1 2015

Research and Markets has announced the addition of the “Metastatic Colorectal Cancer – Pipeline Review, H1 2015” report to their offering. Mabion is one of the companies mentioned in this report.

More: [link]

2015-09-08 Biospace.com/news

Mabion begins pre-registration scientific advice with the European Medicines Agency

Mabion is receiving scientific advice from the European Medicines Agency (EMA) regarding the MabionCD20 drug, used in the treatment of blood cancers and rheumatoid arthritis (RA). This is a preliminary stage prior to the formal application for registration of the drug intended to eliminate obstacles to registration.

More: [link]

2015-09-08 Firstwordpharma.com

Mabion begins pre-registration scientific advice with the European Medicines Agency

Mabion is receiving scientific advice from the European Medicines Agency (EMA) regarding the MabionCD20 drug, used in the treatment of blood cancers and rheumatoid arthritis (RA). This is a preliminary stage prior to the formal application for registration of the drug intended to eliminate obstacles to registration.

More: [link]

2015-09-08 Comparic.pl (author: Łukasz Nowacki)

Mabion [MAB], Tauron [TPE] – Hot companies of the dat

The company has gained more than 7% yesterday on a pretty decent speed. The strong reaction of buyers takes place after a long period of decline and more importantly on the key level of support surrounding PLN 45. As you can see from the chart, this is the level at which price a few times has reacted. In long distance, we still have to deal with the upward trend, but the last one and a half year is almost lateral movement.

More: [link]

2015-08-21 Medgadget.com

Mabion SA Market – Product Pipeline Review, Industry Analysis, Size, Share and Forecast 2015

Mabion SA – Product Pipeline Review – 2015, provides an overview of the Mabion SA’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Mabion SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

More: [link]

 

2015-08-21 Businesswire.com/news

Research and Markets: Rheumatoid Arthritis – Pipeline Review, H1 2015

Research and Markets has announced the addition of the “Rheumatoid Arthritis – Pipeline Review, H1 2015” report to their offering. Mabion is one of the companies mentioned in this report.

More: [link]


2015-08-25
Live-pr.com

New Study: Metastatic Colorectal Cancer – Pipeline Review, H1 2015

Fast Market Research recommends “Metastatic Colorectal Cancer – Pipeline Review, H1 2015” from Global Markets Direct, now available. Mabion is one of the companies mentioned in this report.

More: [link]


2015-08-25 Pr-inside.com/reports

New Market Research Report: Kidney Cancer – Pipeline Review, H1 2015

Fast Market Research recommends “Kidney Cancer – Pipeline Review, H1 2015” from Global Markets Direct, now available. Mabion is one of the companies mentioned in this report.

More: [link]


2015-08-14 Termedia.pl/reumatologia

Step to the registration of biosimilar medicine in EMA. Hope for RA patients.

Mabion is receiving scientific advice from the European Medicines Agency (EMA) regarding the MabionCD20 drug, used in the treatment of blood cancers and rheumatoid arthritis (RA). This is a preliminary stage prior to the formal application for registration of the drug intended to eliminate obstacles to registration.

More: [link]

 

2015-08-19 Stockwatch.pl/wiadomosci (author: Maciej Zbiejcik)

21 companies that are resistant to political turmoil on the WSE

To the portfolios are recommended shares of small and medium-sized enterprises free of political risk and solid results. The game is played mainly on small and medium sized companies. In an interesting technical system are: ACE Budimex, CD Projekt, Duon, Ergis, Raven, Mabion, Mostostal Plock, Mostostal Warszawa, Orbis, Rafako, the Wawel Castle or Zetkama.

More: [link]

 

2015-08-20 Marketresearchstore.com/report

Mabion SA – Product Pipeline Review – 2015

Mabion SA – Product Pipeline Review – 2015, provides an overview of the Mabion SA’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Mabion SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Więcej: [link]

2015-08-14 Parkiet.com

Mabion closer to drug registration

Mabion is receiving scientific advice from the European Medicines Agency (EMA) regarding the MabionCD20 drug, used in the treatment of blood cancers and rheumatoid arthritis (RA). This is a preliminary stage prior to the formal application for registration of the drug intended to eliminate obstacles to registration.

More: [link]

 

2015-08-13 ISBnews

Mabion began scientific advice with the European Medicines Agency regarding MabionCD20

Mabion is receiving scientific advice from the European Medicines Agency (EMA) regarding the MabionCD20 drug, used in the treatment of blood cancers and rheumatoid arthritis (RA). This is a preliminary stage prior to the formal application for registration of the drug intended to eliminate obstacles to registration.

2015-08-13 Wyborcza.biz

Mabion began scientific advice with the European Medicines Agency regarding MabionCD20

Mabion is receiving scientific advice from the European Medicines Agency (EMA) regarding the MabionCD20 drug, used in the treatment of blood cancers and rheumatoid arthritis (RA). This is a preliminary stage prior to the formal application for registration of the drug intended to eliminate obstacles to registration.

More: [link]

 

2015-07-13 Kierunekfarmacja.pl

The first step to the registration of biosimilar drug MabionCD20 with the European Medicines Agency

Mabion is receiving scientific advice from the European Medicines Agency (EMA) regarding the MabionCD20 drug, used in the treatment of blood cancers and rheumatoid arthritis (RA). This is a preliminary stage prior to the formal application for registration of the drug intended to eliminate obstacles to registration.

More: [link]

 

2015-08-13 Portalemedyczne.pl

Mabion began scientific advice with the EMA

Polish company is receiving scientific advice from the European Medicines Agency (EMA) regarding the MabionCD20 drug, used in the treatment of blood cancers and rheumatoid arthritis (RA).

More: [link]

 

2015-08-13 Bio-medicine.org

U.S. Biosimilars Market Worth $11Bn by 2020 – 22% CAGR Forecast for Global Biosimilar Industry in New Research Reports

The Global & USA Biosimilar Market Analysis to 2021 research report indicates a high market potential for biosimilars by 2019 when 50% of the biologics market is forecast to belong to off-patent drugs as there is tremendous interest by big pharma and generics companies in biosimilars industry. Mabion is one of the companies mentioned in this Report.

More: [link]

 

2015-08-13 Thestreet.com

Biosimilars And Follow-On Biologics: World Industry And Market Prospects 2015-2025

Do you want to fully understand the sales potentials for biosimilars? This new analysis provides you with revenue forecasts to 2025 at overall world market, therapeutic class and national level. For those therapies you will receive financial data, R&D trends, opportunities and commercial prospects. Mabion is one of the companies mentioned in this Report.

More: [link]

 

2015-08-13 Pr-inside.com/reports

New Market Report: Retinal Vein Occlusion – Pipeline Review, H1 2015

Global Markets Direct’s, Retinal Vein Occlusion – Pipeline Review, H1 2015′, provides an overview of the Retinal Vein Occlusion’s therapeutic pipeline. Mabion is one of the companies mentioned in this Report.

More: [link]

2015-07-31 12newsnow.com

Psoriatic Arthritis Therapeutic Pipeline Assessment Review H1 2015

The report “Psoriatic Arthritis – Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Psoriatic Arthritis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. The report also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects. Mabion is one of the companies mentioned in this report.

More: [link]

2015-08-05 Bioportfolio.com

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Mabion is one of the companies mentioned in this report.

More: [link]

2015-07-10 4-traders.com

Research and Markets: Ankylosing Spondylitis (Bekhterev’s Disease) Therapeutics Pipeline Review, H1 2015 – 24 Companies & 15 Drug Profiles

Research and Markets has announced the addition of the “Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline Review, H1 2015” report to their offering. Mabion is one of the companies mentioned in this report:

More: [link]


2015-07-02 Parkiet.com

Technical enthusiasm in the stock market inhibits the spectrum Grexitu

On the broad market stood out positively on Wednesday: Eko Export, Komputronik and Mabion. Shares of these companies rose by more than 7 percent

More: [link]


2015-06-25 Parkiet (p. 1)

Top youngest members of the boards

Ten young managers sit on the boards of companies listed on the Warsaw Stock Exchange on Thursday will receive special honors. Among other things, Slawomir Jaros – Member of the Board Mabion

2015-06-23 Advfn.com

Research and Markets: Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Review, H1 2015

Research and Markets  has announced the addition of the “Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Review, H1 2015” report to their offering. Mabion is on of the companies involved in therapeutics development

More: [link]

2015-06-19 Money.pl/tech

Hot topic: the mood in the company Mabion after declining value of the shares. CEO’s comment!

May 27, 2015 r. KCR SA terminated an agreement to conduct research for a drug MabionCD20. KCR SA appointed itself for the temporary restriction of the availability of the drug. Is it threatens the stability of the company and its position in the marketplace? Comments given by Dr. Maciej Wieczorek – CEO of Mabion SA

More: [link]

15-06-11 Biotechnologia.pl
Transfer of knowledge and technology between Polish and Brazil, is it possible?
Mabion continues actions to Mabion CD20 drug registration in the Brazilian market and the company’s acquisition program of public-private partnership (PDP)
More: [link]

2015-06-09 Parkiet (p. 8)
The youngest and the best board members
Slawomir Jaros, who was born in 1980. is a scientist with the flesh and blood. He’s a biotechnologist, who graduated the Warsaw Agricultural University, in the Polish Academy of Sciences received his PhD in biological sciences. Since 2007. He is a board member, but primarily directs research and development center Mabionu.

2015-06-07 Biotechnologia.pl
Hot topic: the mood in the company Mabion after declining value of the shares. CEO’s comment!
May 27, 2015 r. KCR SA terminated an agreement to conduct research for a drug MabionCD20. KCR SA appointed itself for the temporary restriction of the availability of the drug. Is it threatens the stability of the company and its position in the marketplace? Comments given by Dr. Maciej Wieczorek – CEO of Mabion SA
More: [link]

2015-06-03 Parkiet.com
CEO of Mabion buys
After the recent sharp decline in price, Maciej Wieczorek, co-founder, president and one of the main shareholders of biotech company, bought a small package on the WSE.
More: [link]

2015-06-02 Gpwinfostrefa.pl
Mabion extended the agreement for the search of licensee for 3 months
Mabion’s agreement with the Plexus company, which is looking for the company’s licensee for drug MabionCD20, was June 1 extended by three months
More: [link]

2015-06-02 Parkiet.com
Mabion still looking for licensees
Mabion’s agreement with the Plexus company, which is looking for the company’s licensee for drug MabionCD20, was June 1 extended by three months
More: [link]

2015-05-22 Drugpolicycentral.com
Mabion SA – product pipeline market review up to 2014 shared in new research
Global Markets Direct’s, ‘Mabion SA – Product Pipeline Review – 2014’, provides an overview of the Mabion SA’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Mabion SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued Project
More: [link]

2015-05-22 Mynewsdesk.com
Mabion SA – Product Pipeline Review – 2014 According To Radiant Insights
Global Markets Direct’s, ‘Mabion SA – Product Pipeline Review – 2014’, provides an overview of the Mabion SA’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Mabion SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
More: [link]

2015-05-21 Rzeczpospolita (p. B15)
Flagrant weakness WIG20
Data on retail sales and industrial production did not spurred investors to buy shares. It is worth notice that on Wednesday despite the stagnation index, stock quotes as many as 14 companies listed on the WSE reached annual highs. Among them was among others Mabion

2015-05-20 Parkiet.com
Mabion beating new records
The biotech company’s share price once again over the last several sessions beat a new historic record. Mabion, although not yet achieved revenue, is already valued at 800 million zł
More: [link]

2015-05-18 ISBNews
Mabion loss increased on an annual basis to 1.40 million PLN in the first quarter. 2015.
Mabion noted 1.4 million PLN net loss in the first quarter 2015 compared with 0.7 million PLN loss a year earlier, the company said in a report. Operating loss amounted to 1.43 million PLN to 0.69 million PLN loss a year earlier. Revenues from sales amounted to 0.18 million PLN in the first quarter 2015 to 0.36 million PLN a year earlier

2015-05-14 Parkiet.com
Mabion at the top
Share price biosimilar drug maker climbed today to a new historic peak. According to technical analysts can continue to rise
More: [link]

2015-05-09 Parkiet (p. 10)
Providers reports do not such a bad thing
The greatest degree offering “underestimated” the potential Mabionu and Global Cosmedu. In the case of the first company broker, namely Mercurius DM, has priced its securities on offer at 27.8 zł, but investors have lowered their final issue price of 15 PLN. Now the course for WSE hovering around 57 PLN.

2015-05-07 Businesswire.com
Research and Markets: Idiopathic Juvenile Arthritis (Still’s Disease) Therapeutics Pipeline Review 2015
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development: AlphaMab Co., Ltd, Biocon Limited, Epirus Biopharmaceuticals, Inc., Genor BioPharma Co., Ltd., Mabion SA, Oncodesign SA, Panacea Biotec Limited, Pfizer Inc., Sandoz International GmbH, Swedish Orphan Biovitrum AB, UCB S.A.
More: [link]

2015-04-29 Parkiet (p. 6)
Mabion
Mabion signed a licensing agreement with Biolotus within the letter of intent in order to registration, analytics, MabionCD20 drug sales in Brazil, in the longer term – the implementation of the country’s entire manufacturing process up to the finished drugs, according to a company statement

2015-04-28 PAP
Mabion intends to grant the license to the drug MabionCD20 to Brazilian Biolotus
Mabion signed a licensing agreement with Biolotus within the letter of intent in order to registration, analytics, MabionCD20 drug sales in Brazil, in the longer term – the implementation of the country’s entire manufacturing process up to the finished drugs, according to a company statement

2015-04-28 ISBnews
Mabion on the licensing agreement with the Biolotus about cooperation in Brazil
Mabion signed a licensing agreement with Biolotus within the letter of intent in order to registration, analytics, MabionCD20 drug sales in Brazil, in the longer term – the implementation of the country’s entire manufacturing process up to the finished drugs, according to a company statement

2015-04-21 Przemysł Farmaceutyczny (p. 30)
Addicted to biotechnology
About the clinical studies and registration in Brazil Polish monoclonal antibody, about the latest in the world’s biosimilar medicines factory from Konstantynów of Lodz and about his approach to biotechnology, says Dr. Maciej Wieczorek, CEO Mabion SA.

2015-04-21 Przemysł Farmaceutyczny (p. 42)
I hear ” biotechnology “, I think about…
Interview with Dr. Maciej Wieczorek chairman of the board Mabion SA

2015-04-21 Przemysł Farmaceutyczny (p. 4)
Custom-made Fleminga
(…)Mabion SA is at the final stage of Scientific-Industrial Complex Medical Biotechnology in Konstantynow Lodz – it is the only such an advanced manufacturing plant biotech drugs in Poland, and one of the few, and today the most modern in the world (…)

2015-04-17 Comparic.pl
Some information after Thursday’s session on the Warsaw Stock Exchange and most important day chart
Thursday’s session on the Warsaw Stock Exchange is another impressive charge of bulls. (…) Among the companies in this segment should pay attention to MABION, which is nearly three weeks in the correction of previous increases. Today’s move up by 7.41% may be the first sign to complete the correction.
More: [link]

2015-04-13 Inwestycje.pl
Polish biotechnology sector is growing in strength
Thanks to investments made several years ago in the biotechnology industry, today companies from this sector have a strong position not only in Poland, but also in foreign markets. Customers abroad willing reach for the innovative medical devices and drugs. Among the companies that have had international success include Medicalgorithmics, Mabion and Selvita
More: [link]

2014-04-01 Parkiet (p. 9)
Company of the month. Mabion shares have gained 40 percent.
Paper is still accumulated and collected around support levels, and taking into account that the last peak has passed almost a year ago, it can be assumed that with the strengthening of the little companies from the WSE Mabion will move to new historic peaks

2015-04-01 Parkiet (p. 8)
Technicians beat the market with a strong advantage
The highest rate of return on equity brought Mabion’s shares indicated by Piotr Neidk, analyst of DM mBank.

2015-03-27 Parkiet Wyniki Finansowe (p. 5)
Mabion
The article presents the Mabion’s financial results for the fourth quarter 2014.

2015-03-25 Parkiet (p. 4)
Mabion
Mabion is preparing to start work in searching global marketing and distribution partner for the drug MabionCD20, announced CEO Maciej Wieczorek

2015-03-24 ISBNews
Mabionu net loss increased to 4.46 million PLN in 2014
Mabion noted 4.46 million PLN net loss in 2014 against 3.89 million PLN loss a year earlier

2015-03-24 Wyborcza.biz/gieldy
Mabion will start a global searching for the drug distributor of MabionCD20
Mabion is preparing to start work in searching global marketing and distribution partner for the drug MabionCD20, announced CEO Maciej Wieczorek

2015-03-24 ISBNews
Mabion will start a global searching for the drug distributor of MabionCD20
Mabion is preparing to start work in searching global marketing and distribution partner for the drug MabionCD20, announced CEO Maciej Wieczorek

2015-03-19 Healthtechnologynet.com
Biosimilar Monoclonal Antibodies: World Industry and Market Outlook 2015-2025
Biosimilar therapeutic antibodies – see why originator companies should now fear those competitors, discovering their trends and potential sales. What’s the future of biosimilar antibody therapies (mAbs)? Can that emerging market, with vast potential, achieve expected sales growth? See what’s likely there, staying ahead. Mabion is one of many companies discussed in this report.
More: [link]

2015-03-18 Enewsroom.pl
Jaros: Mabion poses on innovative technologies
Mabion is a pioneer in the implementation of sterile disposable materials technology that eliminates the contact of the product with the environment throughout the manufacturing process. Polish company was the first in the world has realized the complete process of biopharmaceutical manufacturing based on this type of solution, and its manufacturing facility in Konstantynow Lodz is the first and currently the only facility in the world where technology-based solutions disposable materials operate on an industrial scale.
More: [link]

2015-03-13 Bitcoinfansite.com
Diabetic Macular Edema Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com – Bitcoin Fan Site
The report “Diabetic Macular Edema – Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Diabetic Macular Edema. Mabion SA is mentioned in “Diabetic Macular Edema – Pipeline Review, H1 2015″ report.
More: [link]

2015-03-10 Enewsroom.pl
Wieczorek, Mabion: Modern biotechnology drugs will be produced in Lodz
Mabion is at an advanced stage of the Scientific-Industrial Complex Medical Biotechnology (large-scale plant), which use permit and certification by the Chief Pharmaceutical Inspectorate are plans still in the first half of 2015.
More: [link]

2015-03-06 Parkiet (p. 2)
Is that looks like the beginning of a bull market?
The course of Thursday’s session gives hope that investors finally got a solid boost purchasing encouraging bolder action. In sWIGSo falls recorded strong growth rate Mabionu (11.09 percent).

2015-03-05 Parkiet (p. 6)
Mabion: End of the study is approaching
In the past five sessions Mabionu shares grew by 20 per cent., To 48.9 zł. Investors liked the decision of the Data and Safety Monitoring Board, which issued a positive report on the security phase III clinical trial of the drug MabionCD20 that leads listed company

2015-03-04 Bloomberg.com
Cancer Cachexia Therapeutics Pipeline Drugs and Companies Review H1 2015 Research Report
ReportsnReports.com offers Cancer Cachexia – Pipeline Review, H1 2015 research report that provides an overview of the Cancer Cachexia’s therapeutic pipeline. Mabion is one of many Companies discussed in this report
More: [link]

2015-03-04 12 newsnow.com
Cancer Cachexia Therapeutics Pipeline Drugs and Companies Review H1 2015 Research Report
ReportsnReports.com offers Cancer Cachexia – Pipeline Review, H1 2015 research report that provides an overview of the Cancer Cachexia’s therapeutic pipeline. Mabion is one of many Companies discussed in this report
More: [link]

2015-03-02 Parkiet.com
Mabion still studying
Mabion qualified for clinical development with MabionCD20 109 percent of total number of patients needed to complete the study – the company said in a statement. On Friday, the commission DSMB (Data and Safety Monitoring Board) issued a positive opinion on the conduct of research on pharmaceuticals.
More: [link]

2015-03-02 PAP
Mabion 109 percent qualified. patients needed to complete clinical studies
Mabion qualified for clinical development with MabionCD20 109 percent of total number of patients needed to complete the study – the company said in a statement. On Friday, the commission DSMB (Data and Safety Monitoring Board) issued a positive opinion on the conduct of research on pharmaceuticals

2015-02-27 Parkiet.com
Mabion finishes with the construction
Mabion Company SA is at an advanced stage of implementation Scientific-Industrial Complex Medical Biotechnology. It is a modern investment with an area of 6.5 thousand. m2 located in Łódź Special Economic Zone
More: [link]

2015-02-26 Businesswire.com
Research and Markets: Metastatic Renal Cell Carcinoma Therapeutics Pipeline Review 2015 – 34 Companies & 38 Drug Profiles
Research and Markets has announced the addition of the “Metastatic Renal Cell Carcinoma – Pipeline Review, H1 2015” report to their offering. Mabion SA is mentioned in “Metastatic Renal Cell Carcinoma – Pipeline Review, H1 2015” report
More: [link]

2015-02-25 Biotechnologia.pl
Be a leader in BioBusiness … Can you? You can!
Mabion Company SA is at an advanced stage of implementation Scientific-Industrial Complex Medical Biotechnology. It is a modern investment with an area of 6.5 thousand. m2 located in Łódź Special Economic Zone
More: [link]

2015-02-25 Finweb.pl
Mabion SA soon new scientific-industrial complex
Mabion Company SA is at an advanced stage of implementation Scientific-Industrial Complex Medical Biotechnology. It is a modern investment with an area of 6.5 thousand. m2 located in Łódź Special Economic Zone
More: [link]

2015-02-20 PAP
A clinical study Mabionu will be increased by approx. 3 months
End of clinical development with MabionCD20 will be increased by approx. 3 months relative to the previous schedule – according to statements made by Mabion representatives

2015-02-19 Inwestycje.pl
DM PKO BP: Daily
Since the beginning of the month course Mabion increases, approaching the resistance in the form of a local maximum at the beginning of January. His break open the way for further upward movement.
More: [link]

2015-02-13 Harvard Business Review (p. 10)
Presidents of the seven editions
CEO Maciej Wieczorek was mentioned in the statement of the Presidents of the companies in the index WIG80..

2015-02-06 Videobasedtutorials.com
Ulcerative Colitis Therapeutics PipelineReview H1 2015 Market Research Report
RnRMarketResearch.com adds “Ulcerative Colitis – Pipeline Review, H1 2015” to its store. This report provides an overview of the Ulcerative Colitis’s therapeutic pipeline and key players involved in the therapeutic development for Botulism and special features on late-stage and discontinued projects.The report also reviews key players involved in the therapeutic development for ulcerative colitis and special features on late-stage and discontinued projects. Companies discussed in this ulcerative colitis pipeline review H1 2015 report includes among others Mabion SA.
More: [link]

2015-02-05 Wfla.com
Ulcerative Colitis Therapeutics PipelineReview H1 2015 Market Research Report
RnRMarketResearch.com adds “Ulcerative Colitis – Pipeline Review, H1 2015” to its store. This report provides an overview of the Ulcerative Colitis’s therapeutic pipeline and key players involved in the therapeutic development for Botulism and special features on late-stage and discontinued projects.The report also reviews key players involved in the therapeutic development for ulcerative colitis and special features on late-stage and discontinued projects. Companies discussed in this ulcerative colitis pipeline review H1 2015 report includes among others Mabion SA.
More: [link]

2015-02-05 Pharmabiz.com
Mabion seeks MabionCD20 drug approval from Argentina to trat blood cancers and RA
Mabion is one step closer to releasing its MabionCD20 drug in Argentina. Together with the intermediary company LKM SA, a petition was submitted in Argentina for approval to start the registration procedure of MabionCD20, a drug used in the treatment of blood cancers and rheumatoid arthritis (RA).
More: [link]

2015-02-04 Biospace.com
Mabion submits registration dossier in Argentyna
Mabion SA is one step closer to releasing its MabionCD20 drug in Argentina. Together with the intermediary company LKM SA, a petition was submitted in Argentina for approval to start the registration procedure of MabionCD20, a drug used in the treatment of blood cancers and rheumatoid arthritis (RA).
More: [link]

2015-02-03 Firstwordpharma.com
Mabion submits registration dossier in Argentyna
Mabion SA is one step closer to releasing its MabionCD20 drug in Argentina. Together with the intermediary company LKM SA, a petition was submitted in Argentina for approval to start the registration procedure of MabionCD20, a drug used in the treatment of blood cancers and rheumatoid arthritis (RA).
More: [link]

2015-02-02 Prlog.org
Biosimilar Monoclonal Antibodies: World Industry and Market Outlook 2015-2025
Revenues for biosimilar monoclonal antibody therapies will exceed $4bn by 2020, predicts new study. Research, data and analyses cover activities of BioXpress, Celltrion, Harvest Moon, Genor Biopharma, Mabion, Pfizer and other companies
More: [link]

2015-02-02 Pr-inside.com
New Market Research Report: Mabion SA (MAB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile
Recently published research from GlobalData, “Mabion SA (MAB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile”, is now available at Fast Market Research.
More: [link]

2015-01-30 Ceepharma.com
Mabion initiates registration of MabionCD20 in Argentina as Phase III trials “near completion””
Mabion SA is one step closer to releasing its MabionCD20 drug in Argentina. Together with the intermediary company LKM SA, a petition was submitted in Argentina for approval to start the registration procedure of MabionCD20, a drug used in the treatment of blood cancers and rheumatoid arthritis (RA).
More: [link]

2015-01-29 Parkiet (p. 6)
Here’s companies in which the OFE lurk under threshold
For which the company is worth paying attention to? It is worth noting that among companies with nearly 5 percent. OFE involving a wide range of companies that have moved their from NewConnect to the main market. Among the others Briju, DTP or Mabion

2015-01-28 Parkiet.com
Mabion submits registration in South America
Mabion SA is one step closer to releasing its MabionCD20 drug in Argentina. Together with the intermediary company LKM SA, a petition was submitted in Argentina for approval to start the registration procedure of MabionCD20, a drug used in the treatment of blood cancers and rheumatoid arthritis (RA).
More:

2015-01-28 Interia.pl/biznes
Mabion submits registration dossier in Argentyna
Mabion SA is one step closer to releasing its MabionCD20 drug in Argentina. Together with the intermediary company LKM SA, a petition was submitted in Argentina for approval to start the registration procedure of MabionCD20, a drug used in the treatment of blood cancers and rheumatoid arthritis (RA).
More: [link]

2015-01-28 Blogspot.com/analiza-techniczna-akcji
Mabion technical analysis 27 January 2015
Mabions technical analysis from 27 January 2015
More: [link]

2015-01-28 Ceepharma.com
Biosimilar drugs – a chance for better access to treatment
Mabion is developing a biosimilar drug for MabThera by Roche. Polpharma also has biosimilar drugs development plans and created a branch dedicated to this field of their activity.
More: <[link]

2015-01-23 Gabionline.net
Mabion starts phase III trial for rituximab biosimilar
Mabion obtained the consent of appropriate regulatory authorities in Croatia, Bosnia and Herzegovina, Serbia and Poland to perform the clinical trial in patients with Diffuse Large B-cell Lymphoma. The study will be carried out in four clinical centers in each the above mentioned countries in cooperation with Altiora d.o.o. Simultaneously Mabion is close to obtain approval to conduct clinical trial in: Bulgaria, Romania, Moldova, Ukraine, Georgia and Hungary.
More: [link]

2015-01-23 Bioportfolio.com
Mabion starts phase III trial for rituximab biosimilar
Mabion obtained the consent of appropriate regulatory authorities in Croatia, Bosnia and Herzegovina, Serbia and Poland to perform the clinical trial in patients with Diffuse Large B-cell Lymphoma. The study will be carried out in four clinical centers in each the above mentioned countries in cooperation with Altiora d.o.o. Simultaneously Mabion is close to obtain approval to conduct clinical trial in: Bulgaria, Romania, Moldova, Ukraine, Georgia and Hungary.
More: [link]

2015-01-09 Pap.pl/Biznes
FDA opinion council regarding the first drug in the US biosimilar beneficial for Mabion (analysis)
Positive opinion of the FDA regarding the registration first biosimilar drug in the US market is beneficial for manufacturers such pharmaceuticals. Mabion, who is working on the EU market launch of its first drug, followed by going to register it in the USA
More: [link]

2015-01-05 Onet.pl/Biznes
Company of day: Mabion
Breakthrough long-term downtrend line should provide further incentives to continue the demand effort. Currently, the nearest resistance determines the October maximum at the altitude 41,99 PLN
More: [link]

2015-01-05 Stooq.pl
Mabion
Mabion has approval from regulatory authorities in Croatia, Bosnia and Herzegovina, Serbia and Poland to conduct supplementary tests (for patients with lymphoma) as part of the clinical development MabionCD20. These countries have to join Bulgaria, Romania, Moldova, Ukraine, Georgia and Hungary.
More: [link]

2015-01-05 Parkiet (p. 2)
Preparations for supplementary tests
Mabion has approval from regulatory authorities in Croatia, Bosnia and Herzegovina, Serbia and Poland to conduct supplementary tests (for patients with lymphoma) as part of the clinical development MabionCD20. These countries have to join Bulgaria, Romania, Moldova, Ukraine, Georgia and Hungary.

2014-12-30 Parkiet.com
Mabion CEO moves the shares
Maciej Wieczorek, president and one of the founders and Mabion major shareholders, moves part of its shares of the biotech company
More: [link]

2014-12-19 PAP
Biosimilar drugs opportunity for small biotech companies (analysis)
To enter the biosimilar market prepares Mabion listed on the Stock Exchange, which this year wants to end his first administration of the drug to patients as part of Phase III clinical trials, and in the middle of next year submit a registration to the European Medicines Agency. The company hopes that at the same time acquire a distribution partner for the EU markets, the US and Japan

2014-12-16 Przemysł Farmaceutyczny (p. 32)
Pharmacy under construction
Scientific-Industrial Complex Medical Biotechnology is a modern investment with an area of 6.5 thousand. m2 in the Łódź Special Economic Zone. Funding for undertaking have been obtained from public offering of EU subsidies, as well as from its own funds. It is the first facility in the world, which have been applied innovative technologies for the production of biotech drugs industrial scale.

2014-12-16 Swiat Przemysłu Farmaceutycznego (p. 20)
Clinical research in the pharmaceutical industry
In the field of clinical research in area of biotechnology active second company managed by Maciej Wieczorek – Mabion SA The company is in advanced work to the registration number of biosimilar drugs, among other things: MabionCD20 for the treatment of blood cancers and rheumatoid arthritis (RA) and MabionHER2 intended for the treatment of breast cancer.

2014-12-16 Parkiet (p. 7)
Mabion
Insiders biotechnology companies in recent transactions for purchases of its shares spent a total of about 360 thousand PLN

2014-12-10 Puls Farmacji (p. 10)
Who give out the cards in the Polish health care system
Maciej Wieczorek, CEO of Mabion SA took 57 place in the ranking of the most influential people in the Polish medicine and health care.

2014-12-10 Puls Farmacji (p. 9)
Research into a cure for lymphoma begins
Mabion SA – Polish, biopharmaceutical Company dedicated to development of therapeutic proteins, mostly monoclonal antibodies – obtained the consent of appropriate regulatory authorities in Croatia, Bosnia and Herzegovina, Serbia and Poland to perform the clinical trial in patients with Diffuse Large B-cell Lymphoma. The study will be carried out in four clinical centers in each the above mentioned countries in cooperation with Altiora d.o.o.

2014-12-02 Outsourcing-pharma.com
Mabion extends agreement with Croatian CRO for Mabthera biosimilar study
Mabion SA – Polish, biopharmaceutical Company dedicated to development of therapeutic proteins, mostly monoclonal antibodies – obtained the consent of appropriate regulatory authorities in Croatia, Bosnia and Herzegovina, Serbia and Poland to perform the clinical trial in patients with Diffuse Large B-cell Lymphoma. The study will be carried out in four clinical centers in each the above mentioned countries in cooperation with Altiora d.o.o.
More: [link]

2014-12-01 Yahoo.com
Research and Markets: Idiopathic Juvenile Arthritis (Still’s Disease) – Pipeline Review, H2 2014
This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still’s Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Mabion is mentioned in report Idiopathic Juvenile Arthritis (Still’s Disease) – Pipeline Review, H2 2014
More: [link]

2014-12-01 Money.pl
Mabion will conduct clinical trials in patients with lymphoma
Mabion SA – Polish, biopharmaceutical Company dedicated to development of therapeutic proteins, mostly monoclonal antibodies – obtained the consent of appropriate regulatory authorities in Croatia, Bosnia and Herzegovina, Serbia and Poland to perform the clinical trial in patients with Diffuse Large B-cell Lymphoma. The study will be carried out in four clinical centers in each the above mentioned countries in cooperation with Altiora d.o.o.
More: [link]

2014-11-28 Pulsmedycyny.pl
Mabion starts clinical researches
Mabion SA – Polish, biopharmaceutical Company dedicated to development of therapeutic proteins, mostly monoclonal antibodies – obtained the consent of appropriate regulatory authorities in Croatia, Bosnia and Herzegovina, Serbia and Poland to perform the clinical trial in patients with Diffuse Large B-cell Lymphoma. The study will be carried out in four clinical centers in each the above mentioned countries in cooperation with Altiora d.o.o.
More: [link]

2014-11-26 Pharmabiz.com
Mabion obtains permission from Croatia, Bosnia and Herzegovina, Serbia & Poland authorities to begin trial in lymphoma patients
Mabion SA – Polish, biopharmaceutical Company dedicated to development of therapeutic proteins, mostly monoclonal antibodies – obtained the consent of appropriate regulatory authorities in Croatia, Bosnia and Herzegovina, Serbia and Poland to perform the clinical trial in patients with Diffuse Large B-cell Lymphoma. The study will be carried out in four clinical centers in each the above mentioned countries in cooperation with Altiora d.o.o.
More: [link]

2014-11-26 Kierunekfarmacja.pl
Mabion has agreed to study patients with lymphoma
Mabion SA – Polish, biopharmaceutical Company dedicated to development of therapeutic proteins, mostly monoclonal antibodies – obtained the consent of appropriate regulatory authorities in Croatia, Bosnia and Herzegovina, Serbia and Poland to perform the clinical trial in patients with Diffuse Large B-cell Lymphoma. The study will be carried out in four clinical centers in each the above mentioned countries in cooperation with Altiora d.o.o.
More: [link]

2014-11-25 Parkiet.com
Mabion starts with research
Mabion SA – Polish, biopharmaceutical Company dedicated to development of therapeutic proteins, mostly monoclonal antibodies – obtained the consent of appropriate regulatory authorities in Croatia, Bosnia and Herzegovina, Serbia and Poland to perform the clinical trial in patients with Diffuse Large B-cell Lymphoma. The study will be carried out in four clinical centers in each the above mentioned countries in cooperation with Altiora d.o.o.
More: [link]

2014-11-25 Interia.pl/Biznes
MAB: Mabion has agreed to study patients with lymphoma
Mabion SA – Polish, biopharmaceutical Company dedicated to development of therapeutic proteins, mostly monoclonal antibodies – obtained the consent of appropriate regulatory authorities in Croatia, Bosnia and Herzegovina, Serbia and Poland to perform the clinical trial in patients with Diffuse Large B-cell Lymphoma. The study will be carried out in four clinical centers in each the above mentioned countries in cooperation with Altiora d.o.o.
More: [link]

2014-11-25 Parkiet.com
Mabion starts with research
Mabion received permission to conduct clinical trials in Croatia, Bosnia and Herzegovina, Serbia and Poland. It applies to patients with diffuse. The study, in collaboration with Altiora d.o.o. will be performed at four clinical sites in each of those countries. At the same time Mabion is close to obtaining approval to conduct research in Bulgaria, Romania, Moldova, Ukraine, Georgia and Hungary. A total of diffuse large study of over 140 patients will in all countries.
More: [link]

2014-11-06 Biospace.com
Mabion: Consultation On FDA Certification
Mabion SA has completed series of consultations with representatives of the American company Regulatory Compiliance Associates (RCA). The purpose of the meeting was to discuss the compatibility of the project Scientific Industrial Complex Medical Biotechnology in Konstantynów Łódz, as well as the manufacturing process of the drug-MabionCD20 in new complexes with the requirements of the US Agency for Food and Drug Administration (FDA).
More: [link]

2014-11-05, Parkiet.com
Mabion after consultations
Mabion SA has completed series of consultations with representatives of the American company Regulatory Compiliance Associates (RCA). The purpose of the meeting was to discuss the compatibility of the project Scientific Industrial Complex Medical Biotechnology in Konstantynów Łódz, as well as the manufacturing process of the drug-MabionCD20 in new complexes with the requirements of the US Agency for Food and Drug Administration (FDA).
More: [link]

2014-11-05, Rp.pl
Mabion after consultations
Mabion SA has completed series of consultations with representatives of the American company Regulatory Compiliance Associates (RCA). The purpose of the meeting was to discuss the compatibility of the project Scientific Industrial Complex Medical Biotechnology in Konstantynów Łódz, as well as the manufacturing process of the drug-MabionCD20 in new complexes with the requirements of the US Agency for Food and Drug Administration (FDA).
More: [link]

2014-10-30, Kierunekfarmacja.pl
Mabion: Positive opinion of the Main Pharmaceutical Inspectorate
Main Pharmaceutical Inspectorate conducted an inspection of the Mabions Research and Development Centre in Łódź, owned by biotech company.
More: [link]

2014-10-29 Parkiet.com
Inspection in Mabion
Main Pharmaceutical Inspectorate conducted an inspection of the Mabions Research and Development Centre in Łódź, owned by biotech company.
More: [link]

2014-10-10 Pr-inside.com
New market study, “Mabion SA – Product Pipeline Review – 2014”, has been published ‘Mabion SA – Product Pipeline Review – 2014’, provides an overview of the Mabion SA’s pharmaceutical research and development focus.
More: [link]

2014-10-09 Biospace.com
Mabion At The Trade Fair CPhl In Paris
Mabion SA will present their achievements during the fair CPhl Worldwide in Paris. The participants of event will have the opportunity to familiarize with the offer of drugs, over whom the company is working – MabionCD20, MabionHER2, MabionVEGF, MabionVEGF-Fab, MabionEGFR – and insulin analogues.
More: [link]

2014-10-07 Newsrm.com
Mabion At The Trade Fair CPhl In Paris
Mabion SA will present their achievements during the fair CPhl Worldwide in Paris. The participants of event will have the opportunity to familiarize with the offer of drugs, over whom the company is working – MabionCD20, MabionHER2, MabionVEGF, MabionVEGF-Fab, MabionEGFR – and insulin analogues.
More: [link]


2014-09-23 Newsfiber.com

Mabion Signed An Agreement For The Realization Of A Clinical Trial Of The Drug MabionHER2 Mabion SA signed an agreement with Altiora d.o.o. for the realization of a clinical research involving the drug MabionHER2 with the participation of patients suffering from breast cancer. The estimated value of the agreement amounts to approximately 5.25 – 6.5 million euros.
More: [link]

2014-09-23 Biospace.com
Mabion Signed An Agreement For The Realization Of A Clinical Trial Of The Drug MabionHER2 Mabion SA signed an agreement with Altiora d.o.o. for the realization of a clinical research involving the drug MabionHER2 with the participation of patients suffering from breast cancer. The estimated value of the agreement amounts to approximately 5.25 – 6.5 million euros.
More: [link]

2014-09-11 Newsfiber.com
Mabion Release: End Of The MabionCD20 Clinical Trial Is Getting Closer
On 29th August 2014 Mabion SA presented to the Data and Safety Monitoring Board (DSMB) – an independent committee of experts in the field of rheumatology, clinical pharmacology and statistics – the clinical and safety data obtained from patients participating in the study MabionCD20. DSMB Committee analyzed patients’ data gathered up to 30th June 2014 (date of database lock for the purpose of processing) contained in the submitted report, as well as data gathered after the date of database lock (not treated statistically – the raw data).
More: [link]

2014-09-11 Biospace.com
Mabion Release: End Of The MabionCD20 Clinical Trial Is Getting Closer
On 29th August 2014 Mabion SA presented to the Data and Safety Monitoring Board (DSMB) – an independent committee of experts in the field of rheumatology, clinical pharmacology and statistics – the clinical and safety data obtained from patients participating in the study MabionCD20. DSMB Committee analyzed patients’ data gathered up to 30th June 2014 (date of database lock for the purpose of processing) contained in the submitted report, as well as data gathered after the date of database lock (not treated statistically – the raw data).
More: [link]

2014-09-11 Clinicalspace.com
Mabion Release: End Of The MabionCD20 Clinical Trial Is Getting Closer
On 29th August 2014 Mabion SA presented to the Data and Safety Monitoring Board (DSMB) – an independent committee of experts in the field of rheumatology, clinical pharmacology and statistics – the clinical and safety data obtained from patients participating in the study MabionCD20. DSMB Committee analyzed patients’ data gathered up to 30th June 2014 (date of database lock for the purpose of processing) contained in the submitted report, as well as data gathered after the date of database lock (not treated statistically – the raw data).
More: [link]

2014-09-06 Parkiet (p. 3)

Mabion
Mabion signed an agreement with the company Altiora doo, the subject of which is the realization by Altiora clinical trial of the drug MabionHER2 involving patients suffering from breast cancer

2014-09-05 Pap.pl
Mabion has an agreement of a clinical trial for a drug MabionHER2 for 22.1 million zł
Mabion signed an agreement with the company Altiora doo, the subject of which is the realization by Altiora clinical trial of the drug MabionHER2 involving patients suffering from breast cancer
More: [link]

2014-09-05 Parkiet.com
Mabion is preparing for further research
Mabion signed an agreement with the company Altiora doo, the subject of which is the realization by Altiora clinical trial of the drug MabionHER2 involving patients suffering from breast cancer
More: [link]

2014-09-05 Pb.pl
Mabion Altiora has a contract with a value of at least 22 million zł
Mabion signed an agreement with the company Altiora doo, the subject of which is the realization by Altiora clinical trial of the drug MabionHER2 involving patients suffering from breast cancer
More: [link]

2014-09-05 Wp.pl
Mabion Altiora has a contract with a value of at least 22 million zł
Mabion signed an agreement with the company Altiora doo, the subject of which is the realization by Altiora clinical trial of the drug MabionHER2 involving patients suffering from breast cancer
More: [link]

2014-09-01 Kierunekfarmacja.pl
Nearly 80% of patients qualified in the main study MabionCD20
Mabion received another positive opinion from the Committee DSMB, which evaluates the clinical study of the company over its drug MabionCD2O. – The Commission sees no impediment to the continuation of research in accordance with the approved protocol. No problem with side effects, patients reasonably well correspond to the drug – says Maciej Wieczorek, CEO of Mabion SA
More: [link]

2014-09-01 Bankier.pl
Mabion in mid 2015 MabionCD20 will submit a registration dossier (interview)
Mabion to the end of 2014 will complete recruitment and administration of doses in a pivotal clinical study of the drug MabionCD20, and in mid-2015 would be able to submit a registration dossier – said the CEO. He added that an additional test will end no later than the basic
More: [link]

2014-09-01 Parkiet (p. 4)
Recruitment of patients by the end of this year
Mabion received another positive opinion from the Committee DSMB, which evaluates the clinical study of the company over its drug MabionCD2O. – The Commission sees no impediment to the continuation of research in accordance with the approved protocol. No problem with side effects, patients reasonably well correspond to the drug – says Maciej Wieczorek, CEO of Mabion SA

2014-08-31 Money.pl
Mabion working on a new drug. Received a positive opinion
Mabion received another positive opinion from the Committee DSMB, which evaluates the clinical study of the company over its drug MabionCD2O. – The Commission sees no impediment to the continuation of research in accordance with the approved protocol. No problem with side effects, patients reasonably well correspond to the drug – says Maciej Wieczorek, CEO of Mabion SA
More: [link]

2014-08-30 Gpwinfostrefa.pl
Mabion qualified to test 77.1 percent. patients necessary for its completion
Mabion received another positive opinion from the Committee DSMB, which evaluates the clinical study of the company over its drug MabionCD2O. – The Commission sees no impediment to the continuation of research in accordance with the approved protocol. No problem with side effects, patients reasonably well correspond to the drug – says Maciej Wieczorek, CEO of Mabion SA
More: [link]

2014-08-07 Gazeta Farmaceutyczna (p. 15)

Summer news
Mabion has signed a letter of intent with Brazilian company Biolotus Biotech concerning cooperation in Brazil. Biolotus is therefore on his part to take an action leading to the registration of Mabion’s products in Brazil. MabionCD20 as a biosimilar product to the drug Rituxan is about to be the main driver of a strategy aimed at creating not only a factory but also the analytical laboratory in Brazil. The factory will be built over the next five years.

2014-07-17 Parkiet.com
Mabion issued shares
Mabion – the company that produces biosimilars – issued 0.51 million of L shares and gained PLN 21 million. As it was previously announced new values were taken  by the company’s founders.
More: [link]

2014-07-16 Finweb.pl
Mabion can obtain large resources
According to the Statute of Mabion the Board of Directors is authorized to increase the share capital within the authorized capital by not more than PLN 51 thousand. Now the authorities decided to take an advantage of remuneration which is granted to them.
More: [link]

2014-07-16 Stooq.com
Mabion decided about the issue of series L shares without pre-emptive rights
The Board of Mabion adopted a resolution regarding the increase of the share capital within the authorized capital by issuing shares of Series L pre-emptive rights.
More: [link]

2014-07-16 Wp.pl/Finanse
Mabion decided about the issue of series L shares without pre-emptive rights
The Board of Mabion adopted a resolution regarding the increase of the share capital within the authorized capital by issuing shares of Series L pre-emptive rights.
More: [link]

2014-07-16 Wyborcza.biz
Mabion decided about the issue of series L shares without pre-emptive rights
The Board of Mabion adopted a resolution regarding the increase of the share capital within the authorized capital by issuing shares of Series L pre-emptive rights.
More: [link]

2014-06-10 Parkiet.com
Mabion enters the Brazilian market
Biotechnology company started actions in the field of registration, distribution and sale of the drug MabionCD20 in the Brazilian market. The aim of the program is to join a public-private partnership coordinated by the Brazilian Ministry of Health. Mabion signed a letter of intent on cooperation with Biolotus Biotech in Brazil. Biolotus is about to take actions leading to the registration of products offered by Mabionu regarding the Brazilian market.
More: [link]

2014-06-10 Rp.pl/Ekonomia
Mabion enters the Brazilian marke
Biotechnology company started actions in the field of registration, distribution and sale of the drug MabionCD20 in the Brazilian market. The aim of the program is to join a public-private partnership coordinated by the Brazilian Ministry of Health. Mabion signed a letter of intent on cooperation with Biolotus Biotech in Brazil. Biolotus is about to take actions leading to the registration of products offered by Mabionu regarding the Brazilian market.
More: [link]

2014-06-10 Parkiet.com
USA on Mabion’s target
Company Mabion enters the next phase for certification of the FDA for the Scientific and Industrial Complex of Medical Biotechnology. The company has signed a letter of intent with the American company Regulatory Compliance Associates (RCA) regarding consulting services in adapting scientific and industrial complex to the requirements of the U.S. Agency for Food and Drug Administration (FDA) in order to obtain a certificate for the center which is an essential element of the registration and sale of drugs in the United States.
More: [link]

2014-06-09 ISBNews
Mabion has an agreement with RSA on the consultation of the creation of a production complex
Mabion signed an agreement with an American company – Regulatory Compliance Associates Inc. – on the providing consulting services by RCA regarding preparation the scientific-industrial complex in Konstantynów Łódzki and adapting it to requirements of the U.S. Agency for Food and Drug Administration (FDA).

2014-06-09 ISBNews
Mabion has a intention letter with the Biolotus company on cooperation in Brazil
Mabion signed a intention letter with Biolotus Biotech regarding cooperation in Brazil – was given by Mabion in a special statement. In the first period of cooperation the aim is to register, analyze and sale the drug MabionCD20 in the territory of Brazil and ultimately the implementation of the entire manufacturing process in a factory which is about to be built after 5 years since the registration.

2014-06-09 PAP
Mabion has a intention letter with the Biolotus company on cooperation in Brazil
Mabion signed a intention letter with Biolotus Biotech regarding cooperation in Brazil – was given by Mabion in a special statement. In the first period of cooperation the aim is to register, analyze and sale the drug MabionCD20 in the territory of Brazil and ultimately the implementation of the entire manufacturing process in a factory which is about to be built after 5 years since the registration.

2014-06-09 Parkiet (p. 4)
Half of clinical trials behind us
Interview with the President of the Board at Mabion – Maciej Wieczorek – conducted by Maciej Rudke.

2014-06-06 Parkiet.com
Biotechnology, a high risk, high profits
One promising biotech companies is Mabion, whose strategy is to develop, register and market drugs similar to the reference preparations shortly after the expiry of patents to protect them. It is not about standard drugs based on chemical compounds, but biotech drugs produced by living cells.
More: [link]

2014-06-02 Parkiet (p. 11)
Biosimilars market waiting flowering and acquisitions years
Biotech medicines are now among the best selling in the world. No wonder that willing to produce is more and more. Dark horse may be Polish Mabion, which dates back to the capitalization of the WSE 0.5 billion zł.

2014-05-30 Biotechnologia.pl
Quo vadis Poland? Perspective the Polish biotechnology market. part I
During the meeting BioForum 2014 Dr. Maciej Wieczorek, president of the companies Mabion SA and Celon Pharma SA (Poland) led a plenary lecture entitled “Quo Vadis Poland? Perspective the Polish market of biotechnology. Part I.”. Presentation was about current situation of Poland to bio-business market,  as well pointed out the advantages of joining the biotech region of Central and Eastern Europe (…).
More: [link]

2014-05-29 Puls Biznesu (p. 3)
Explore and develop
(…) Mabion is working to prepare for registration of biosimilar medicines, including MabionCD20 for the treatment of blood cancers and rheumatoid arthritis (RA) and to be MabionHER2 breast cancer therapy. Develop also antibodies antyVEGF that will be used in the treatment of eyes diseases, and antyEGFR for the treatment of gastrointestinal cancers, including colorectal cancer and pancreatic cancer. (…)

2014-05-29 Rp.pl/Ekonomia
Mabion is looking for distributor
Polish biotechnology company, developing and implementing specialized market biosimilars latest generation – signed an agreement with Plexus Ventures LLC agreement on the acquisition of new customers to buy the drug MabionCD20. Plexus will be responsible for identifying potential licensees, arranging meetings and lead to the finalization of the contract.
More: [link]

2014-05-29 Wyborcza.biz
Plexus Ventures will look for contractors for Mabionu
Polish biotechnology company, developing and implementing specialized market biosimilars latest generation – signed an agreement with Plexus Ventures LLC agreement on the acquisition of new customers to buy the drug MabionCD20. Plexus will be responsible for identifying potential licensees, arranging meetings and lead to the finalization of the contract.
More: [link]

2014-05-28 Parkiet (p. 3)
Small and medium-sized companies will still grow
All exchanges Companies nice surprise results for the quarter l, and their rates are significantly below the target prices of recommendation. For which companies to bet? (…) Positive recommendations with a price significantly above the market in recent weeks gathered, amongst others, Mabion, ABC Data, and Magellan. (…) This year, the course of Mabion has already gained 46 percent. and is currently hovering around 51 zł. Mercurius Brokerage House price target in next 12 months, set at 70.3 zł. On publication of the report rate went up by 7 percent.

2014-05-27 Puls Biznesu (p. 19)
More detail, more profits
(…) In the last week, investors bought shares to the races, among others, Paged, Mabion, Otmuchów or Harper. (…)

2014-05-26 Parkiet.com
Mabion begins research on lymphoma
Mabion signed contract with Altiora d.o.o. for the study of patients with lymphoma in Polish, Croatia, Bosnia, Serbia, Hungary, Bulgaria, Moldova and Montenegro, the company said. The contract value amounts to almost 1.5 million euro, and the expected date of fulfillment of the obligations under the contract is 31 December 2014
More: [link]

2014-05-26 Rynekzdrowia.pl
Mabion is doing research on biosimilar lymphoma drug and rheumatoid arthritis
Mabion signed contract with Altiora d.o.o. for the study of patients with lymphoma in Polish, Croatia, Bosnia, Serbia, Hungary, Bulgaria, Moldova and Montenegro, the company said. The contract value amounts to almost 1.5 million euro, and the expected date of fulfillment of the obligations under the contract is 31 December 2014
More: [link]

2014-05-26 Wp.pl/Finanse
Mabion has a contract for research into lymphoma in 8 countries
Mabion signed contract with Altiora d.o.o. for the study of patients with lymphoma in Polish, Croatia, Bosnia, Serbia, Hungary, Bulgaria, Moldova and Montenegro, the company said. The contract value amounts to almost 1.5 million euro, and the expected date of fulfillment of the obligations under the contract is 31 December 2014
More: [link]

2014-05-23 Puls Biznesu (p. 20)
Investors are once again hunting for bears
(…) Recommendations also reminded investors of Amica, Loan Collection and Mabion (…) Mabion deserves – in the opinion of Mercurius DM experts – at a higher valuation, because the probability of success of the flagship product of biotechnology companies, a medicine used in the treatment of cancer.

2014-05-21 Puls Biznesu (p. 17)
Mercurius recalled the Mabion
Mercurius DM, which in recent years has been offering the emissions Mabionu estimated current value of the shares of this biotech company to 50.4 zł. Target pricing for 12 months, assuming the completion of this time of clinical trials on the drug MabionCD20 is 70.3 zł. On Tuesday, shares Mabionu prices rose by up to 6.9 percent., To 48.98 zł.

2014-05-21 Parkiet (p. 7)
The report raised Exchange
Mercurius DM, which in recent years has been offering the emissions Mabionu estimated current value of the shares of this biotech company to 50.4 zł. Target pricing for 12 months, assuming the completion of this time of clinical trials on the drug MabionCD20 is 70.3 zł. On Tuesday, shares Mabionu prices rose by up to 6.9 percent., To 48.98 zł.

2014-05-20 Stooq.pl
Mercurius DM predicts 12-month valuation of Mabionu to 70.3 zł
Mercurius DM analysts began issuing recommendations for the company Mabion valuing the company at 70.3 qualities zł. Brokerage House was offering the issues Mabionu. Mercurius DM projected valuation of Mabionu for 12 months at 70.3 zł assuming the end of that time clinical trials of a drug MabionCD20 – According to a report dated May 13. The report was issued at the rate of 44 zł, and on Monday at the closing per share Mabionu paid 45.8 zł. Mercurius DM was offering the issues Mabionu.
More: [link]

2014-05-20 Interia.pl/Biznes
DM Mercurius valued Mabion
Mercurius DM analysts began issuing recommendations for the company Mabion valuing the company at 70.3 qualities zł. Brokerage House was offering the issues Mabionu. Mercurius DM projected valuation of Mabionu for 12 months at 70.3 zł assuming the end of that time clinical trials of a drug MabionCD20 – According to a report dated May 13. The report was issued at the rate of 44 zł, and on Monday at the closing per share Mabionu paid 45.8 zł. Mercurius DM was offering the issues Mabionu.
More: [link]

2014-05-20 Bankier.pl
Mercurius DM predicts 12-month valuation of Mabionu to 70.3 zł
Mercurius DM analysts began issuing recommendations for the company Mabion valuing the company at 70.3 qualities zł. Brokerage House was offering the issues Mabionu. Mercurius DM projected valuation of Mabionu for 12 months at 70.3 zł assuming the end of that time clinical trials of a drug MabionCD20 – According to a report dated May 13. The report was issued at the rate of 44 zł, and on Monday at the closing per share Mabionu paid 45.8 zł. Mercurius DM was offering the issues Mabionu.
More: [link]

2014-05-20 Rzeczpospolita (p.4)
From idea to market
Company Mabion SA will build at the Medical University of Lodz complex scientific-industrial medical biotechnology, which will produce medicines that help in the fight against blood cancer and necessary for the treatment of breast cancer. This will be the first plant in Poland producing this type of medication. Factory will be launched in 2014. Research and development was led by a team of biotechnologists Mabionu in collaboration with researchers from medical schools. Mabion invested in the implementation of the drug 100 million zł.

2014-05-13 Wyborcza.biz
Mabion gained more than 53 million zł from the issuance of shares of series K and L
Mabion gained more than 53 million zł through the issue of shares of series K and L. Institutional investors took the 790 000 shares of series F, while the founders Mabion 510 000 shares of series L. In both cases, the price was 41 zł per share. The funds will be allocated to research and to supplement working capital, said the company.
More: [link]

2014-05-13 Rynekzdrowia.pl
Mabion: more than 53 million zł from the new issue
Mabion gained more than 53 million zł through the issue of shares of series K and L. Institutional investors took the 790 000 shares of series F, while the founders Mabion 510 000 shares of series L. In both cases, the price was 41 zł per share. The funds will be allocated to research and to supplement working capital, said the company.
More: [link]

2014-05-13 Wp.pl/Finanse
Mabion gained more than 53 million zł from the issuance of shares of series K and L
Mabion gained more than 53 million zł through the issue of shares of series K and L. Institutional investors took the 790 000 shares of series F, while the founders Mabion 510 000 shares of series L. In both cases, the price was 41 zł per share. The funds will be allocated to research and to supplement working capital, said the company.
More: [link]

2014-05-13 Parkiet (p. 5)
Cash provided
Mabion gained more than 53 million zł through the issue of shares of series K and L. Institutional investors took the 790 000 shares of series F, while the founders Mabion 510 000 shares of series L. In both cases, the price was 41 zł per share. The funds will be allocated to research and to supplement working capital, said the company.

2014-05-12 Gpwinfostrefa.pl
Mabion issued 790 thousand shares at 41 zł, and has buyers for another 510 thousand shares
Mabion issued 790 thousand series K shares at a price 41 zł, allowing gained 32.39 mln zł – the company said in a statement. At the same time Mabion signed with major shareholders preliminary agreements cover 510 thousand. L series shares, after 41 zł per share. “Series L Shares will be issued and acquired by investors subject to registration by the registration court statute changes involving the authorization of the Board to increase the share capital within the authorized capital and to obtain the consent of the Supervisory Board at the height of the above issue price”.
More: [link]

2014-05-12 Bankier.pl
Mabion issued 790 thousand shares at 41 zł, and has buyers for another 510 thousand shares
Mabion issued 790 thousand series K shares at a price 41 zł, allowing gained 32.39 mln zł – the company said in a statement. At the same time Mabion signed with major shareholders preliminary agreements cover 510 thousand. L series shares, after 41 zł per share. “Series L Shares will be issued and acquired by investors subject to registration by the registration court statute changes involving the authorization of the Board to increase the share capital within the authorized capital and to obtain the consent of the Supervisory Board at the height of the above issue price”.
More: [link]

2014-05-05 Kierunekfarmacja.pl
Biotechnology breakthrough
Mabion as first in the world is using on an industrial scale bioreactor processes based on a single technology (disposables). Thanks to research significantly increases the scale of production of monoclonal antibodies from 200 to 2500 liters, without noticing any differences in quality.
More: [link]

2014-05-05 Parkiet (p. 14)
Biotechnology can give still a lot to earn
(…) Mabion not yet achieved significant sales revenue. Currently focused on clinical trials of its first drug MabionCD20 that can be completed by the end of this year. After statistical analysis of the results of the company may, at the start of 2015. Y submit a registration application to the European Medicines Agency. In such a scenario MabionCD20 could be registered in the EU in the first quarter of 2016 (…)

2014-04-30 Puls Biznesu (p. 2)
Union transferred us a half a billion
In the article there is a comment by Maciej Wieczorek President Mabion and Celon Pharma – “Our presence in the EU judge very positively. What may seem surprising, the biggest plus was the need to adapt to the high standards and requirements of the EU. Although they cost and time-consuming, after 10 years, I can say that it was worth it. Why? Today is committed to quality and no self-respecting entrepreneurs do not go for shortcuts, but will think three times before you do something at the border or in violation of the law. In the pharmaceutical industry, in which I work, these aspects are particularly important. We are also better perceived because we received a new brand of the EU and the huge financial support (…). ”

2014-04-30 Parkiet (p. 4)
Mabion has a good chance to sell all shares
Biotechnology company can obtain from the market for more than 32 mln zł, so that clinical trials will complete its first drug. From the information “Parquet” that Mabion found buyers for all of the shares offered 0.79 mln K series representing 7.7 percent. In the increased capital. Demand was significantly exceed supply and some investors have received one-third of the shares, which subscribed. – the offer lasts – says only Michael Kowalczewski, President of Mercurius DM, which is an offering. – the share subscription agreement have not yet been included – marks.

2014-04-30 Parkiet.com
Mabion increases the scale
The company develops biosimilars drugs as the world’s first used on an industrial scale bioreactor processes based on a single technology. Mabion announces that it has successfully conducted the world’s first industrial process recombinant CHO cells by means of a bioreactor Kuhner based on a single technology (called disposables). The studies used the bioreactor prototype 2500 l capacity allowing a mixed culture system orbital shaking (orbital shaking).
More: [link]

2014-04-30 Rynekzdrowia.pl
Cell culture in a new bioreactor prototype
The company develops biosimilars drugs as the world’s first used on an industrial scale bioreactor processes based on a single technology. Mabion announces that it has successfully conducted the world’s first industrial process recombinant CHO cells by means of a bioreactor Kuhner based on a single technology (called disposables). The studies used the bioreactor prototype 2500 l capacity allowing a mixed culture system orbital shaking (orbital shaking).
More: [link]

2014-04-30 Biotechnologia.pl
Mabion pioneered the use of bioreactors based on a single technology
The company develops biosimilars drugs as the world’s first used on an industrial scale bioreactor processes based on a single technology. Mabion announces that it has successfully conducted the world’s first industrial process recombinant CHO cells by means of a bioreactor Kuhner based on a single technology (called disposables). The studies used the bioreactor prototype 2500 l capacity allowing a mixed culture system orbital shaking (orbital shaking).
More: [link]

2014-04-30 Interia.pl/Biznes
Mabion implements industrial process
The company develops biosimilars drugs as the world’s first used on an industrial scale bioreactor processes based on a single technology. Mabion announces that it has successfully conducted the world’s first industrial process recombinant CHO cells by means of a bioreactor Kuhner based on a single technology (called disposables). The studies used the bioreactor prototype 2500 l capacity allowing a mixed culture system orbital shaking (orbital shaking).
More: [link]

2014-04-30 Rp.pl/Ekonomia
Mabion increases the scale
The company develops biosimilars drugs as the world’s first used on an industrial scale bioreactor processes based on a single technology. Mabion announces that it has successfully conducted the world’s first industrial process recombinant CHO cells by means of a bioreactor Kuhner based on a single technology (called disposables). The studies used the bioreactor prototype 2500 l capacity allowing a mixed culture system orbital shaking (orbital shaking).
More: [link]

2014-04-25 Interia.pl
Mabion: GMS decides on a new issue
On 23th April General Meeting Shareholders of Mabion SA approved the issuance to 790 000 K shares without subscription rights. The proceeds from issuance will be used primarily for: adaptation and certification of the new Science and Industrial Complex Medical Biotechnology to the requirements of the FDA (the U.S. drug agency) to cover the medical market and increase cost of clinical development MabionCD20 and supplement working capital, mainly due to shifts in settlements of EU funds and taxes. Offering Mabion SA shares is Mercurius Brokerage House.
Read more; [link]

2014-04-25 Puls Farmacji
Mabion release a new tranche of shares
On 23th April General Meeting Shareholders of Mabion SA approved the issuance to 790 000 K shares without subscription rights. The proceeds from issuance will be used primarily for: adaptation and certification of the new Science and Industrial Complex Medical Biotechnology to the requirements of the FDA (the U.S. drug agency) to cover the medical market and increase cost of clinical development MabionCD20 and supplement working capital, mainly due to shifts in settlements of EU funds and taxes. Offering Mabion SA shares is Mercurius Brokerage House.
Read more: [link]

2014-04-24 Wyborcza.biz
Mabion shareholders decided to issue up to 790 thousand. series K shares without pp
On 23th April General Meeting Shareholders of Mabion SA approved the issuance to 790 000 K shares without subscription rights. The proceeds from issuance will be used primarily for: adaptation and certification of the new Science and Industrial Complex Medical Biotechnology to the requirements of the FDA (the U.S. drug agency) to cover the medical market and increase cost of clinical development MabionCD20 and supplement working capital, mainly due to shifts in settlements of EU funds and taxes. Offering Mabion SA shares is Mercurius Brokerage House.
Read more: [link]

2014-04-24 Bankier.pl
Mabionu GMS approved the issuance of up to 790 thousand. series K shares
On 23th April General Meeting Shareholders of Mabion SA approved the issuance to 790 000 K shares without subscription rights. The proceeds from issuance will be used primarily for: adaptation and certification of the new Science and Industrial Complex Medical Biotechnology to the requirements of the FDA (the U.S. drug agency) to cover the medical market and increase cost of clinical development MabionCD20 and supplement working capital, mainly due to shifts in settlements of EU funds and taxes. Offering Mabion SA shares is Mercurius Brokerage House.
Read more: [link]

2014-04-24 Biotechnologia.pl
New Mabion share issue approved
On 23th April General Meeting Shareholders of Mabion SA approved the issuance to 790 000 K shares without subscription rights. The proceeds from issuance will be used primarily for: adaptation and certification of the new Science and Industrial Complex Medical Biotechnology to the requirements of the FDA (the U.S. drug agency) to cover the medical market and increase cost of clinical development MabionCD20 and supplement working capital, mainly due to shifts in settlements of EU funds and taxes. Offering Mabion SA shares is Mercurius Brokerage House.
Read more: [link]

2014-04-24 ISBNews
Mabion shareholders decided to issue up to 790 thousand. series K shares without pp
On 23th April General Meeting Shareholders of Mabion SA approved the issuance to 790 000 K shares without subscription rights. The proceeds from issuance will be used primarily for: adaptation and certification of the new Science and Industrial Complex Medical Biotechnology to the requirements of the FDA (the U.S. drug agency) to cover the medical market and increase cost of clinical development MabionCD20 and supplement working capital, mainly due to shifts in settlements of EU funds and taxes. Offering Mabion SA shares is Mercurius Brokerage House.

2014-04-24 PAP
Mabionu GMS approved the issuance of up to 790 thousand. series K shares
On 23th April General Meeting Shareholders of Mabion SA approved the issuance to 790 000 K shares without subscription rights. The proceeds from issuance will be used primarily for: adaptation and certification of the new Science and Industrial Complex Medical Biotechnology to the requirements of the FDA (the U.S. drug agency) to cover the medical market and increase cost of clinical development MabionCD20 and supplement working capital, mainly due to shifts in settlements of EU funds and taxes. Offering Mabion SA shares is Mercurius Brokerage House.

2014-04-22 Parkiet (p. 3)
High interest in Mabion
Convened on 23th April extraordinary general meeting shareholders of Mabion will decide about issue maximally 0.79 million shares of K representing 7.7 percent. in increased capital. The company plans to acquire about 40 min zł. According to our information, the manufacturer of biosimilars should not have problems with placing the issue.

2014-04-22 Interia.pl
Mabion signed an agreement in Iceland
Mabion SA signed an agreement with LYFIS ehf. From Iceland on the registration, distribution and sale of the drug MabionCD20 in this country.
Read more: [link]

2014-04-22 Parkiet.com
Mabion signed an agreement in Iceland
Mabion SA signed an agreement with LYFIS ehf. From Iceland on the registration, distribution and sale of the drug MabionCD20 in this country.
Read more: [link]

2014-04-22 Rynekzdrowia.pl
Mabion SA brings drug MabionCD20 to Iceland
Mabion SA signed an agreement with LYFIS ehf. From Iceland on the registration, distribution and sale of the drug MabionCD20 in this country.
Read more: [link]

2014-04-22 Money.pl
Iceland next goal for the Polish drug maker
Mabion SA signed an agreement with LYFIS ehf. From Iceland on the registration, distribution and sale of the drug MabionCD20 in this country.
Read more: [link]

2014-04-22 Biotechnologia.pl
Mabion signed an agreement in Iceland
Mabion SA signed an agreement with LYFIS ehf. From Iceland on the registration, distribution and sale of the drug MabionCD20 in this country.
Read more: [link]

2014-04-07 Stockwatch.pl
5 intriguing companies with the ambition to profit from innovation
Recently loudly made by the biotechnology Mabion. The Company convenes the NWZA on April 23. Planned meeting is to decide the fate of emissions to 790 thousand. K series shares with pre-emptive rights. Currently the share capital is divided into 9.5 million shares.
Read more: [link]

2014-04-07 Parkiet.com
Insiders bought more
People with confidential information issued on share purchases 11 million zł in March, with sales gained 7 million zł. (…) The shares of their companies accumulated managers Mabion
Read more: [link]

2014-04-07 Parkiet (p. 4)
Insiders bought more
People with confidential information issued on share purchases 11 million zł in March, with sales gained 7 million zł. (…) The shares of their companies accumulated managers Mabion